Search Within

Ravinder K Grewal

Formats
  1. Journal Article (55)
  2. Meeting Abstract (18)
  3. Book Section (4)
  4. Research Letter (2)
  5. Book Whole (1)
  6. Editorial (1)
  7. Review (1)
Groups
  1. Molecular Imaging and Therapy Service (82)
  2. Radiology, Department of (82)
  3. Department of Medicine (56)
  4. Survivorship Research (45)
  5. Division of Subspecialty Medicine (40)
  6. GSK Faculty (40)

More Groups

People
  1. Steven Larson (34)
  2. Robert Tuttle (28)
  3. Heiko Schoder (22)
  4. Alan Ho (16)
  5. James Fagin (15)
  6. Ronald Ghossein (12)

More People

Years
  1. 2024 (3)
  2. 2023 (4)
  3. 2022 (5)
  4. 2021 (2)
  5. 2020 (3)
  6. 2019 (5)

More Years

Publications
  1. Journal of Nuclear Medicine (11)
  2. Clinical Nuclear Medicine (7)
  3. Journal of Clinical Oncology (7)
  4. Thyroid (7)
  5. Blood (4)
  6. European Journal of Nuclear Medicine and Molecular Imaging (3)

More Publications

Publishers
  1. Elsevier Inc. (11)
  2. Society of Nuclear Medicine (11)
  3. Lippincott Williams & Wilkins (10)
  4. American Society of Clinical Oncology (7)
  5. Mary Ann Liebert, Inc (7)
  6. Springer (7)

More Publishers

Results (82)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Phase II study of PDR001 in combination with MAPK pathway inhibitors in patients with radioactive-refractory differentiated thyroid cancer (DTC)
    Meeting Abstract

    Wong, W.; Sherman, E. J.; Kriplani, A.; Michel, L.; Zhi, I.; Hung, T. K. W.; Dunn, L.; Grewal, R. K.; Krishnamoorthy, G.; Ostrovnaya, I.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • [(18)F]TFB PET/CT misses intense [(124)I]iodine-avid metastases after redifferentiation therapy in metastatic thyroid cancer
    Journal Article

    Backhaus, P.; Pentlow, K. S.; Ho, A. L.; Mauguen, A.; Fagin, J. A.; Pillarsetty, N. V. K.; Lyashchenko, S. K.; Burnazi, E.; Ghossein, R. A.; Chhabra, S.; more...
    EJNMMI Research (2024)

    Fulltext@MSK | Save
  • Toward individualized dosimetry for radiopharmaceutical therapy in day-to-day clinical practice of nuclear oncology: Overcoming heterogeneity of radiation-absorbed dose to tumor and critical organs
    Editorial

    Bodei, L.; Tuttle, R. M.; Grewal, R. K.; Mauguen, A.; Augensen, F.; Abusamra, M.; Mahajan, S.; Jayaprakasam, V. S.; Osborne, J. R.; Haque, S.; more...
    European Journal of Nuclear Medicine and Molecular Imaging (2024)

    Fulltext@MSK | Save
  • Prospective comparison of F-18-TFB and I-124 PET/CT in metastatic thyroid cancer
    Meeting Abstract

    Backhaus, P.; Pentlow, K.; Ho, A.; Mauguen, A.; Fagin, J.; Pillarsetty, N. V. K.; Lyashchenko, S.; Abusamra, M.; Larson, S.; Schoder, H.; more...
    Journal of Nuclear Medicine (2023)

    Fulltext@MSK | Save
  • Prospective comparison of F-18-TFB and I-124 PET/CT in metastatic thyroid cancer
    Meeting Abstract

    Backhaus, P.; Pentlow, K.; Ho, A. L.; Mauguen, A.; Fagin, J. A.; Pillarsetty, N. V. K.; Lyashchenko, S. K.; Burnazi, E.; Ghossein, R. A.; Chhabra, S.; more...
    European Journal of Nuclear Medicine and Molecular Imaging (2023)

    Fulltext@MSK | Save
  • The use of single-timepoint images to link administered radioiodine activity (MBq) to a prescribed lesion radiation-absorbed dose (cGy): A regression-based prediction interval tool for the management of well-differentiated thyroid cancer patients
    Journal Article

    Mauguen, A.; Grewal, R. K.; Augensen, F.; Abusamra, M.; Mahajan, S.; Jayaprakasam, V. S.; Osborne, J.; Haque, S.; Wong, B. Z. Y.; Ghossein, R. A.; more...
    European Journal of Nuclear Medicine and Molecular Imaging (2023)

    Fulltext@MSK | Save
  • Genomic and transcriptomic characteristics of metastatic thyroid cancers with exceptional responses to radioactive iodine therapy
    Journal Article

    Boucai, L.; Saqcena, M.; Kuo, F.; Grewal, R. K.; Socci, N.; Knauf, J. A.; Krishnamoorthy, G. P.; Ryder, M.; Ho, A. L.; Ghossein, R. A.; more...
    Clinical Cancer Research (2023)

    Fulltext@MSK | Save
  • Phase 2 of trametinib plus radioiodine in RAS-mutant and wild-type, radioiodine-refractory thyroid cancer (ETCTN9446)
    Meeting Abstract

    Burman, B.; Tuttle, R. M.; Grewal, R. K.; Sherman, E. J.; Baxi, S. S.; Boucai, L.; Sabra, M.; Fish, S.; Pentlow, K. S.; Haque, S.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Treatment response and clinical outcomes of well-differentiated high-grade neuroendocrine tumors to lutetium-177-DOTATATE
    Journal Article

    Raj, N.; Coffman, K.; Le, T.; Do, R. K. G.; Rafailov, J.; Choi, Y.; Chou, J. F.; Capanu, M.; Dunphy, M.; Fox, J. J.; more...
    Neuroendocrinology (2022)

    Fulltext@MSK | Save
  • Next-generation ALK inhibitors are highly active in ALK-positive large B-cell lymphoma
    Research Letter

    Soumerai, J. D.; Rosenthal, A.; Harkins, S.; Duffy, J.; Mecca, C.; Wang, Y.; Grewal, R. K.; El-Jawahri, A. R.; Liu, H.; Menard, C.; more...
    Blood (2022)

    Fulltext@MSK | Save